مركـز الكويـت لمكافحـة السرطـان
Kuwait Cancer Control Center

Modified XELIRI
(AXEPT Trial)

MXELIRI-0-03-CN-GI

Ministry of Health

Name:
Nationality:
Gender/Age:

File #:
Civil ID:
DOB:

Ht (cm):
Wt (Kg):
BSA (m²):

Indication(s): Advanced stage colorectal cancer, palliative.
Central line: ☐ Available ☐ NA **Allergies:** ☐ NKA ☐ Yes, specify; ______________

Parameters: Initiate treatment only if ANC ≥ 1500; HB ≥ 80; Plt ≥ 75,000; CrCl > 45 ml/min.

Pre-treatment Medications: (30-60 min before starting treatment)
Ondansetron 8 mg PO/IV
Dexamethasone 10 mg PO/IV

Standard Protocol:

DRUG	DOSE	ADMINISTRATION	DAYS
IRINotecan	200 mg/m²	IV in 500 mL D5W over 90 min.	D1
CAPEcitabine	800 mg/m² PO bid	To be given with a large glass of water within 30 min	D1 - 14
To be repeated every 3 weeks, usually for 6-8 cycles but can be continued until disease progression or intolerable toxicity.			

Treatment Description:

Cycle	Day	Date	IRINotecan	CAPEcitabine	Physician	Consultant
C# __	D1			XXXXXXX		
	D1 - 14		XXXXXXX			

Cycle	Day	Date	IRINotecan	CAPEcitabine	Physician	Consultant
C# __	D1			XXXXXXX		
	D1 - 14		XXXXXXX			

Cycle	Day	Date	IRINotecan	CAPEcitabine	Physician	Consultant
C# __	D1			XXXXXXX		
	D1 - 14		XXXXXXX			

Important Notes:
Reported grade 3/4 toxicities: ☐ None ☐ Hematological ☐ Non-Hematological
If yes; Did it indicate hospitalization? ☐ Yes ☐ No
Did it indicate chemo-delay for ≥ 7 days? ☐ Yes ☐ No
Did it indicate dose reduction? ☐ Yes ☐ No
Did it indicate G-CSF support? ☐ Yes ☐ No